NASDAQ:PRQR - ProQR Therapeutics Stock Price, Forecast & News

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PRQR stock has increased by 2.6% and is now trading at $7.18. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ProQR Therapeutics.

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for ProQR Therapeutics.

ProQR Therapeutics NV (NASDAQ:PRQR) released its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.04. View ProQR Therapeutics' earnings history.

3 brokerages have issued twelve-month target prices for ProQR Therapeutics' stock. Their forecasts range from $25.00 to $40.00. On average, they expect ProQR Therapeutics' stock price to reach $30.67 in the next year. This suggests a possible upside of 327.1% from the stock's current price. View analysts' price targets for ProQR Therapeutics.

Media stories about PRQR stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ProQR Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutProQR Therapeutics.

ProQR Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 688,800 shares, an increase of 17.6% from the February 27th total of 585,800 shares. Based on an average daily volume of 197,000 shares, the short-interest ratio is presently 3.5 days. Approximately 2.5% of the shares of the stock are sold short. View ProQR Therapeutics' Current Options Chain.

Some companies that are related to ProQR Therapeutics include Karyopharm Therapeutics (KPTI), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Corcept Therapeutics (CORT), Innoviva (INVA), Ligand Pharmaceuticals (LGND), Tricida (TCDA), I-Mab (ARQT), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), Heron Therapeutics (HRTX), Zogenix (ZGNX), ZEALAND PHARMA/S (ZEAL), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include Bioamber (BIOA), GALAPAGOS NV/S (GLPG), Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Uniqure (QURE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Verastem (VSTM) and Progenics Pharmaceuticals (PGNX).

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

ProQR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (6.79%), Jennison Associates LLC (5.33%), FMR LLC (2.39%), UBS Group AG (1.03%), Cowen AND Company LLC (0.21%) and Renaissance Technologies LLC (0.17%).

PRQR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, and Renaissance Technologies LLC.

PRQR stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Cowen AND Company LLC, UBS Group AG, California Public Employees Retirement System, Goldman Sachs Group Inc., Geode Capital Management LLC, Oxford Asset Management LLP, and Ellington Management Group LLC.

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRQR stock can currently be purchased for approximately $7.18.

ProQR Therapeutics has a market capitalization of $354.48 million. The biopharmaceutical company earns $-63,260,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe. View additional information about ProQR Therapeutics.

The official website for ProQR Therapeutics is http://www.proqr.com/.

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]